McKenna Logan R, Edil Barish H
Department of Surgery, University of Colorado, Academic Office One, Aurora, CO, USA.
Gland Surg. 2014 Nov;3(4):258-75. doi: 10.3978/j.issn.2227-684X.2014.06.03.
Pancreatic neuroendocrine tumors (pNETs) are relatively rare tumors comprising 1-2% of all pancreas neoplasms. In the last 10 years our understanding of this disease has increased dramatically allowing for advancements in the treatment of pNETs. Surgical excision remains the primary therapy for localized tumors and only potential for cure. New surgical techniques using laparoscopic approaches to complex pancreatic resections are a major advancement in surgical therapy and increasingly possible. With early detection being less common, most patients present with metastatic disease. Management of these patients requires multidisciplinary care combining the best of surgery, chemotherapy and other targeted therapies. In addition to surgical advances, recently, there have been significant advances in systemic therapy and targeted molecular therapy.
胰腺神经内分泌肿瘤(pNETs)是相对罕见的肿瘤,占所有胰腺肿瘤的1%-2%。在过去十年中,我们对这种疾病的认识有了显著提高,这使得pNETs的治疗取得了进展。手术切除仍然是局限性肿瘤的主要治疗方法,也是唯一可能治愈的方法。采用腹腔镜方法进行复杂胰腺切除术的新手术技术是手术治疗的一项重大进展,并且越来越可行。由于早期检测并不常见,大多数患者就诊时已出现转移性疾病。对这些患者的管理需要多学科护理,将最佳的手术、化疗和其他靶向治疗结合起来。除了手术进展外,最近全身治疗和靶向分子治疗也取得了重大进展。